Faculty of Medicine, School of Pharmacy and David R. Bloom Center for Pharmacy, Institute for Drug Research, Hebrew University of Jerusalem, Jerusalem, Israel.
National Center for Epilepsy, Sandvika, Norway.
Epilepsia. 2020 Nov;61(11):2340-2364. doi: 10.1111/epi.16725. Epub 2020 Nov 14.
Since 1992, the Eilat Conferences have provided a forum for all stakeholders in the epilepsy community to appraise the latest data on new antiepileptic drugs and emergency seizure treatments, including, in recent years, updates on progress with the development of novel monitoring and therapeutic devices. Because of the COVID-19 pandemic, the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV) was held as a fully virtual conference on July 27-30, 2020 for the sessions on drugs and on August 3, 2020 for the sessions on devices, and was attended during the 5 days by >500 participants from 63 countries. This progress report summarizes key preclinical and initial (phase 1) clinical data on eight investigational treatments that are currently in early development, including 2-deoxy-D-glucose, GAO-3-02, JNJ-40411813, NBI-921352, NTX-001, sec-butylpropylacetamide, XEN1101, and XEN496. This report provides an overview of current scenarios in the area of treatment discovery and development. The information presented illustrates a variety of innovative strategies, including exploration of compounds with novel mechanisms of action, transplantation of interneurons into epileptogenic brain regions, and the targeting of rare, previously neglected syndromes.
自 1992 年以来，埃拉特会议为癫痫社区的所有利益相关者提供了一个论坛，以评估新型抗癫痫药物和紧急癫痫治疗的最新数据，包括近年来新型监测和治疗设备开发进展的最新信息。由于 COVID-19 大流行，第十五届新型抗癫痫药物和设备埃拉特会议（EILAT XV）于 2020 年 7 月 27 日至 30 日作为一个完全虚拟会议举行，会议分别讨论了药物和设备，在为期 5 天的会议期间，来自 63 个国家的 500 多名参与者参加了会议。本进展报告总结了目前处于早期开发阶段的八种研究性治疗方法的关键临床前和初步（I 期）临床数据，包括 2-脱氧-D-葡萄糖、GAO-3-02、JNJ-40411813、NBI-921352、NTX-001、sec-丁基丙酰胺、XEN1101 和 XEN496。本报告概述了治疗发现和开发领域的当前情况。所呈现的信息展示了各种创新策略，包括探索具有新型作用机制的化合物、将中间神经元移植到致痫脑区，以及针对罕见的、以前被忽视的综合征。
